CONNECT BIOPHARMA HOLDINGS LTD (CNTB)
Health Care · Biopharmaceutical development (monoclonal antibodies) · NASDAQ
Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD.
What CONNECT BIOPHARMA HOLDINGS LTD does
Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation human monoclonal IgG4 antibody designed to target interleukin-4-receptor alpha (IL-4Rα) to inhibit IL-4 and IL-13 signaling in eosinophilic-driven respiratory diseases. In May 2025, the company initiated two Phase 2 trials: Seabreeze STAT ASTHMA and Seabreeze STAT COPD, evaluating rademikibart plus standard of care versus placebo in patients with acute exacerbations.
Themes: respiratory diseases, asthma treatment, COPD treatment, immunology / inflammation, clinical-stage biopharma
Fundamentals
- Price$2.36 as of 2026-08-21 close
- Market cap$149M as of 2026-08-21
- 1-year return+36.4% 2025-08-21 close $1.73 → 2026-08-21 close $2.36
- P/En/a negative earnings
- Net margin-21243.3% as of 2026-08-24
- ROE-122.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-99.8% FY2025 vs FY2024, SEC XBRL
- Beta-0.20 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How CNTB compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CONNECT BIOPHARMA HOLDINGS LTD looks technically
CONNECT BIOPHARMA HOLDINGS LTD (CNTB) is trading 3.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 34 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 6 trading days ago. It is 38.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.3% below its 200-day average, the long-term trend line — a long-term downtrend | -3.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.24 | $2.24 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.44 | $2.44 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.64. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 34 trading days ago — a "death cross", a bearish long-term signal | 34 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.3 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($2.04 to $2.64) — its "stochastic" reading is 53 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 53.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.82 | $3.82 |
|---|---|---|
| From the 52-week high | it is 38.2% below its 52-week high (its highest price of the past year) | -38.2% |
| Above the 52-week low | it is 91.9% above its 52-week low (its lowest price of the past year) | +91.9% |
| Below the 52-week high | it is 38.2% below its highest point of the past year | 38.2% |
| Since a 20-day breakout | it made a new 20-day high about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 15 trading days ago | 15 sessions |
| All-time high | its highest closing price on record is $29.27 (set on 2021-08-10) | $29.27 |
| Given back of the 52-week move | over the past year its closes ranged ($1.32 to $3.69), and it has given back around half of its rise from last year’s low — 56% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.15 to $2.22. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 56.0% |
| From the all-time high | it is 91.9% below its all-time high | -91.9% |
| Nearest price level | it is trading 6.1% above a support level at $2.21 — a price it turned at twice since 2025-09-03, most recently on 2026-02-06. Since 2024-08-21 it has 9 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.1% |
| All-time low | its lowest closing price on record is $0.51 (set on 2025-04-04) | $0.51 |
| Above the all-time low | it is 362.7% above its all-time low | +362.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 77% of it) | 77th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1748 between its high and its low — about 7.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1748 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.89 and $2.59 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.89 – $2.24 – $2.59 |
| Typical daily range (% of price) | its price moves about 7.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.4% |
| Stretch from the 200-day average | it is trading 0.5 daily ranges below its 200-day average price (3.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.5 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.10× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.8% since the prior reading | +1.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 4.1% above the previous close 13 sessions ago and has not traded back through the level it left behind at 1.97 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.1% |
| Gap filled | a 2.5% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.5 percentage points (the stock gained 6.8% while the market gained 2.3%) | +4.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.1 percentage points (the stock gained 0.0% while the market gained 3.1%) | -3.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 22.0 percentage points (the stock lost 10.9% while the market gained 11.1%) | -22.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 15.9 percentage points (the stock gained 36.4% while the market gained 20.5%) | +15.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.4% of the share price. | -0.6% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.48 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -4.9% |
|---|
Price levels it has turned at before
CNTB last closed at $2.36 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.21 | Support | 6.1% below the last close | turned there twice · 2025-09-03 to 2026-02-06 |
| $2.57 | Resistance | 9.0% above the last close | turned there four times · 2025-12-12 to 2026-05-04 |
| $2.03 | Support | 13.8% below the last close | turned there three times · 2025-10-09 to 2026-01-12 |
| $2.71 | Resistance | 14.8% above the last close | turned there twice · 2026-05-13 to 2026-05-26 |
| $2.81 | Resistance | 19.3% above the last close | turned there twice · 2026-02-03 to 2026-07-10 |
| $1.46 | Support | 38.0% below the last close | turned there twice · 2025-10-29 to 2025-11-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.64.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · Analyst price target recently RAISED · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.13 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$7.25 range $4.00 – $10.00; median $7.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CNTB
- Consensus EPS estimate-$0.26 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products and a history of operating losses, raising significant doubt about its ability to continue as a going concern.","High dependency on the successful clinical development and regulatory approval of its lead product candidate, rademikibart.","Exposure to volatility in the biopharmaceutical sector and potential future dilutive financing requirements."]
What changed in the latest 10-Q
AI-assisted comparison of CNTB's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) includes reference to Section 27A of the Securities Act in forward-looking statements section
- Newer filing (2026-05-12) adds 'commitments' and 'goals' to the list of forward-looking statement identifier words
- Newer filing (2026-05-12) references '2025 Annual Report' while older filing references '2024 Annual Report'
- Newer filing (2026-05-12) includes paragraph about significant developments with specific dates: August 2025 partnership with Ickey Woods, September 2, 2025 ADR termination and Nasdaq listing, Q3 2025 European Respiratory Society Congress 2025 presentation, and expectation to report topline data in first half of 2026
- Newer filing (2026-05-12) includes detailed rademikibart clinical data regarding lung function improvements, type 2 inflammatory markers, and eosinophil/fractional exhaled nitric oxide levels
- Newer filing (2026-05-12) includes reference to Phase 2 acute exacerbation studies in asthma and COPD
- Newer filing (2026-05-12) references '2024 Annual Report' in Critical Accounting Estimates section
- Removed:
- Older filing (2025-11-12) states forward-looking statements section is 'The following discussion and other parts of this quarterly report contain forward-looking statements' — this phrasing is not in newer filing
- Older filing (2025-11-12) includes statement 'Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein...' — this statement is truncated/removed in newer filing excerpt
- Older filing (2025-11-12) references 'Part II, Item 1A under the heading Risk Factors' while newer filing references 'Part I'
- Older filing (2025-11-12) includes 'Overview' section describing Connect Biopharma as clinical-stage biopharmaceutical company — this section is not present in newer filing excerpt
- Reworded:
- Newer filing (2026-05-12) states 'This Quarterly Report on Form 10-Q, including the sections entitled...' versus older filing's 'The following discussion and other parts of this quarterly report contain...'
- Newer filing (2026-05-12) adds 'including statements regarding our strategy, future events, future financial condition, revenues or performance, future operations' with more detailed enumeration than older filing
- Newer filing (2026-05-12) uses 'These statements may be identified by the use of words such as' versus older filing's 'These statements are often identified by the use of words such as'
- Newer filing (2026-05-12) states 'We have based these forward-looking statements largely on our current assumptions, expectations and projections' versus older filing's 'We have based these forward-looking statements largely on our current expectations and projections' (adds 'assumptions')
- Newer filing (2026-05-12) references 'date of this Quarterly Report on Form 10-Q' versus older filing's 'date of this quarterly report'
- Newer filing (2026-05-12) states 'substantial known and unknown risks, uncertainties and assumptions' versus older filing's 'risks, uncertainties and assumptions' (adds 'substantial known and unknown')
- Notes:
- Newer filing text appears truncated at end of Forward-Looking Statements section; full comparison of that section cannot be completed
- Older filing text is truncated at end of Research and Development Expense section; cannot assess if additional content differs
Risk Factors
- Added:
- New disclosure in 2026 filing regarding the Holding Foreign Insiders Accountable Act (HFIAA) signed December 18, 2025, requiring directors and officers of foreign private issuers to comply with Section 16(a) insider reporting requirements beginning March 18, 2026
- Private placement financing activity in Q1 2026: issuance of 6,130 thousand ordinary shares for $18.6 million
- License and collaboration revenues of $169 thousand in Q1 2026 (compared to $0 in Q1 2025)
- Subscription receivable of $2.669 million as non-cash financing activity in Q1 2026
- Accrued but unpaid private placement issuance costs of $1.577 million in Q1 2026
- Removed:
- Statement that officers, directors, and principal shareholders are not subject to 'the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act' was modified to clarify only short-swing profit recovery (Section 16(b)) applies to them, as officers and directors now must comply with Section 16(a) reporting requirements
- Specific reference to 'Regulation FD' removed from the list of exemptions (now covered under broader HFIAA disclosure)
- Reworded:
- Explanatory note language changed regarding Section 16 compliance: older filing stated officers, directors, and principal shareholders are 'not subject to the reporting and short-swing profit recovery provisions'; newer filing specifies they remain exempt from Section 16(b) but clarifies directors and officers must comply with Section 16(a) beginning March 18, 2026
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs. nine months ended September 30, 2025) making some financial comparisons not directly comparable
- Newer filing text appears truncated at the end of the cash flows statement provided, so full comparison of that section was not possible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 0 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($371610) · 0 sells — 1 buying insider
- Last 180 days2 buys ($4M) · 0 sells — 1 buying insider
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-05-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CNTB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
CNTB had 2,060,037 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CNTB had 3.27% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.02 days to cover at the same settlement.
- Reported short interest (shares) 2,060,037
- Short interest (% of shares outstanding) 3.27%
- Prior settlement (shares) 2,062,435
- Reported change -0.12%
- Days to cover (reported) 8.02
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Regeneron Pharmaceuticals (REGN)
- AstraZeneca (AZN)
- GlaxoSmithKline (GSK)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CNTB vs…
Frequently asked questions
What does CONNECT BIOPHARMA HOLDINGS LTD (CNTB) do?
Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San Diego dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation human monoclonal IgG4 antibody designed to target interleukin-4-receptor alpha (IL-4Rα) to inhibit IL-4 and IL-13 signaling in eosinophilic-driven respiratory diseases.
What sector is CONNECT BIOPHARMA HOLDINGS LTD (CNTB) in?
CONNECT BIOPHARMA HOLDINGS LTD (CNTB) is classified in the Health Care sector. Its industry is Biopharmaceutical development (monoclonal antibodies). It trades on NASDAQ.
Who are CONNECT BIOPHARMA HOLDINGS LTD's (CNTB) competitors?
Notable peers of CONNECT BIOPHARMA HOLDINGS LTD (CNTB) include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GlaxoSmithKline and Amgen. This peer set is informational only — not financial advice.
Is CONNECT BIOPHARMA HOLDINGS LTD (CNTB) overbought or oversold right now?
CONNECT BIOPHARMA HOLDINGS LTD (CNTB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CNTB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.